Nov 2, 2016 9:20 am EDT EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Sep 13, 2016 8:30 am EDT EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
Sep 12, 2016 8:30 am EDT EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
Sep 6, 2016 8:30 am EDT EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
Aug 10, 2016 4:50 pm EDT EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Aug 1, 2016 8:30 am EDT EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
Jun 1, 2016 8:30 am EDT EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery